Table Info

Test	Intake mean [n = 26 (SD)]	Follow-up mean [n = 26 (SD)]	Change score mean (SD)	t-value (25)	P value
PHQ-9	12.9 (6.5)	10.9 (6.1)	–2.0 (6.4)	1.6	0.128
GAD-7	10.7 (7.3)	9.2 (6.0)	–1.5 (6.3)	1.3	0.222
BPI	74.1 (16.6)	70.2 (14.7)	–4.0 (15.0)	1.3	0.191

Declarations

Acknowledgements

We thank all patients and staff who were involved in the project. We acknowledge Fonda Betts, Tanya Adams, and Greenleaf Medical Clinic.

Author contributions

ENRS: Data curation, Formal analysis, Investigation, Methodology, Validation, Writing—original draft. CAM: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Validation, Writing—review & editing. LAL: Formal analysis, Investigation, Methodology, Validation, Writing—review & editing. JD: Data curation, Project administration, Supervision, Writing—review & editing. AC and KR: Data curation, Investigation, Validation, Writing—review & editing. CP: Writing—review & editing. WJP: Conceptualization, Funding acquisition, Resources, Writing—review & editing. AMB: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing—original draft.

Conflicts of interest

CAM has received consulting fees or honoraria from Andira, Active Patch Technologies, Dosist, Strainprint, Emerald Health Therapeutics, Sapphire Clinics, Aleafia, Spectrum, Tilray, Numinus, Aurora and MD Briefcase. She is on the Board of Directors for the Green Organic Dutchmen. The other authors report no potential conflicts.

Ethical approval

Study ethics for this chart review were approved by the Clinical Research Ethics Board of the University of British Columbia (H17-03359) and complies with Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Data cannot be shared due to the stipulations of the ethics approval to ensure privacy of the patients involved.

Funding

AMB was funded by an NSERC grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Galgano M, Toshkezi G, Qiu X, Russell T, Chin L, Zhao LR. Traumatic brain injury: current treatment strategies and future endeavors. Cell Transplant. 2017;26:1118–30. [DOI] [PubMed] [PMC]

Whiteneck GG, Cuthbert JP, Corrigan JD, Bogner JA. Risk of negative outcomes after traumatic brain injury: a statewide population-based survey. J Head Trauma Rehabil. 2016;31:E43–54. [DOI] [PubMed]

Coronado VG, McGuire LC, Sarmiento K, Bell J, Lionbarger MR, Jones CD, et al. Trends in traumatic brain injury in the U.S. and the public health response: 1995–2009. J Safety Res. 2012;43:299–307. Erratum in: J Safety Res. 2014;48:117. [DOI] [PubMed]

Gardner AJ, Zafonte R. Chapter 12 - Neuroepidemiology of traumatic brain injury. Handb Clin Neurol. 2016;138:207–23. [DOI] [PubMed]

Public Health Agency of Canada. Injury in review, 2020 edition: spotlight on traumatic brain injuries across the life course [Internet]. Ottawa: Public Health Agency of Canada; [cited 2021 Oct 10]. Available from: https://www.canada.ca/en/public-health/services/injury-prevention/canadian-hospitals-injury-reporting-prevention-program/injury-reports/2020-spotlight-traumatic-brain-injuries-life-course.html

Chen A, Bushmeneva K, Zagorski B, Colantonio A, Parsons D, Wodchis WP. Direct cost associated with acquired brain injury in Ontario. BMC Neurol. 2012;12:76. [DOI] [PubMed] [PMC]

Cassidy JD, Carroll LJ, Peloso PM, Borg J, von Holst H, Holm L, et al.; WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO collaborating centre task force on mild traumatic brain injury. J Rehabil Med. 2004;36:28–60. [DOI] [PubMed]

Ng SY, Lee AYW. Traumatic brain injuries: pathophysiology and potential therapeutic targets. Front Cell Neurosci. 2019;13:528. [DOI] [PubMed] [PMC]

Daneshvar DH, Riley DO, Nowinski CJ, McKee AC, Stern RA, Cantu RC. Long-term consequences: effects on normal development profile after concussion. Phys Med Rehabil Clin N Am. 2011;22:683–700. [DOI] [PubMed] [PMC]

10.

Saulino PA, Greenwald BD, Gordon DJ. The changing landscape of the use of medical marijuana after traumatic brain injury: a narrative review. Brain Inj. 2021;35:1510–20. [DOI] [PubMed]

11.

Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40:23–30. [DOI] [PubMed]

12.

Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med. 2019;233:181–92. [DOI] [PubMed]

13.

Hawley LA, Ketchum JM, Morey C, Collins K, Charlifue S. Cannabis use in individuals with spinal cord injury or moderate to severe traumatic brain injury in Colorado. Arch Phys Med Rehabil. 2018;99:1584–90. [DOI] [PubMed]

14.

Hill MN, Barr AM, Ho WS, Carrier EJ, Gorzalka BB, Hillard CJ. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J Neurochem. 2007;103:47–56. [DOI] [PubMed]

15.

Rouhollahi E, MacLeod BA, Barr AM, Puil E. Cannabis extract CT-921 has a high efficacy-adverse effect profile in a neuropathic pain model. Drug Des Devel Ther. 2020;14:3351–61. [DOI] [PubMed] [PMC]

16.

Barr AM, Phillips AG. Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of D-amphetamine. Pharmacol Biochem Behav. 2002;71:293–9. [DOI] [PubMed]

17.

Henderson LA, Kotsirilos V, Cairns EA, Ramachandran A, Peck CC, McGregor IS. Medicinal cannabis in the treatment of chronic pain. Aust J Gen Pract. 2021;50:724–32. [DOI] [PubMed]

18.

Belardo C, Iannotta M, Boccella S, Rubino RC, Ricciardi F, Infantino R, et al. Oral cannabidiol prevents allodynia and neurological dysfunctions in a mouse model of mild traumatic brain injury. Front Pharmacol. 2019;10:352. [DOI] [PubMed] [PMC]

19.

Alalawi A, Dodu JC, Woolley-Roberts M, Brodie J, Di Marzo V, Soderstrom K. Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model. Neuropharmacology. 2019;158:107716. [DOI] [PubMed]

20.

Braun M, Khan ZT, Khan MB, Kumar M, Ward A, Achyut BR, et al. Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain Behav Immun. 2018;68:224–37. [DOI] [PubMed] [PMC]

21.

Hergert DC, Robertson-Benta C, Sicard V, Schwotzer D, Hutchison K, Covey DP, et al. Use of medical cannabis to treat traumatic brain injury. J Neurotrauma. 2021;38:1904–17. [DOI] [PubMed] [PMC]

22.

Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial^*. Crit Care Med. 2002;30:548–54. [DOI] [PubMed]

23.

Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M, et al.; Pharmos TBI investigators. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5:38–45. [DOI] [PubMed]

24.

Lawrence DW, Foster E, Comper P, Langer L, Hutchison MG, Chandra T, et al. Cannabis, alcohol and cigarette use during the acute post-concussion period. Brain Inj. 2020;34:42–51. [DOI] [PubMed]

25.

Durand E, Chevignard M, Watier L, Fix M, Weiss JJ, Pradat-Diehl P. Traumatic brain injury among young offenders in France based on the results of the Fleury TBI study. Cogent Soc Sci. 2017;3:1398125.

26.

Turna J, Balodis I, Munn C, Van Ameringen M, Busse J, MacKillop J. Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. Compr Psychiatry. 2020;102:152188. [DOI] [PubMed]

27.

Lo LA, MacCallum CA, Yau JC, Panenka WJ, Barr AM. Factors associated with problematic cannabis use in a sample of medical cannabis dispensary users. Psychiatr Clin Psychopharmacol. 2022;32:262–7.

28.

Berey BL, Aston ER, Gebru NM, Merrill JE. Differences in cannabis use characteristics, routines, and reasons for use among individuals with and without a medical cannabis card. Exp Clin Psychopharmacol. 2023;31:14–22. [DOI] [PubMed]

29.

Gottschling S, Ayonrinde O, Bhaskar A, Blockman M, D’Agnone O, Schecter D, et al. Safety considerations in cannabinoid-based medicine. Int J Gen Med. 2020;13:1317–33. [DOI] [PubMed] [PMC]

30.

MacCallum CA, Lo LA, Pistawka CA, Boivin M. A clinical framework for evaluating cannabis product quality and safety. Cannabis Cannabinoid Res. 2023;8:567–74. [DOI] [PubMed] [PMC]

31.

Brunetti P, Pichini S, Pacifici R, Busardò FP, Del Rio A. Herbal preparations of medical cannabis: a vademecum for prescribing doctors. Medicina (Kaunas). 2020;56:237. [DOI] [PubMed] [PMC]

32.

Practice standard: cannabis for medical purposes [Internet]. Vancouver: College of Physicians and Surgeons of British Columbia; [cited 2021 Oct 10]. Available from: https://www.cpsbc.ca/files/pdf/PSG-Cannabis-for-Medical-Purposes.pdf

33.

MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. Eur J Intern Med. 2021;89:10–8. [DOI] [PubMed]

34.

Tse L, Schwarz SK, Bowering JB, Moore RL, Barr AM. Incidence of and risk factors for delirium after cardiac surgery at a quaternary care center: a retrospective cohort study. J Cardiothorac Vasc Anesth. 2015;29:1472–9. [DOI] [PubMed]

35.

Tse L, Bowering JB, Schwarz SK, Moore RL, Burns KD, Barr AM. Postoperative delirium following transcatheter aortic valve implantation: a historical cohort study. Can J Anaesth. 2015;62:22–30. [DOI] [PubMed]

36.

Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7. [DOI] [PubMed]

37.

Kroenke K, Spitzer RL, Williams JB. The PHQ-9. J Gen Intern Med. 2001;16:606–13. [DOI] [PubMed] [PMC]

38.

Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20:309–18. [DOI] [PubMed]

39.

Cuttler C, Mischley LK, Sexton M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 2016;1:166–75. [DOI] [PubMed] [PMC]

40.

Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43:34–51. [DOI] [PubMed] [PMC]

41.

Munivenkatappa A, Agrawal A, Shukla DP, Kumaraswamy D, Devi BI. Traumatic brain injury: does gender influence outcomes? Int J Crit Illn Inj Sci. 2016;6:70–3. [DOI] [PubMed] [PMC]

42.

Gupte R, Brooks W, Vukas R, Pierce J, Harris J. Sex differences in traumatic brain injury: what we know and what we should know. J Neurotrauma. 2019;36:3063–91. [DOI] [PubMed] [PMC]

43.

Silverberg ND, Gardner AJ, Brubacher JR, Panenka WJ, Li JJ, Iverson GL. Systematic review of multivariable prognostic models for mild traumatic brain injury. J Neurotrauma. 2015;32:517–26. [DOI] [PubMed]

44.

Rosenthal MS, Pipitone RN. Demographics, perceptions, and use of medical marijuana among patients in Florida. Med Cannabis Cannabinoids. 2021;4:13–20. [DOI] [PubMed] [PMC]

45.

Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95:986–95.E1. [DOI] [PubMed] [PMC]

46.

Troutt WD, DiDonato MD. Medical cannabis in Arizona: patient characteristics, perceptions, and impressions of medical cannabis legalization. J Psychoactive Drugs. 2015;47:259–66. [DOI] [PubMed]

47.

Mahabir VK, Merchant JJ, Smith C, Garibaldi A. Medical cannabis use in the United States: a retrospective database study. J Cannabis Res. 2020;2:32. [DOI] [PubMed] [PMC]

48.

Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J. 2005;2:18. [DOI] [PubMed] [PMC]

49.

Stubbs JL, Thornton AE, Gicas KM, O’Connor TA, Livingston EM, Lu HY, et al. Characterizing traumatic brain injury and its association with losing stable housing in a community-based sample. Can J Psychiatry. 2022;67:207–15. [DOI] [PubMed] [PMC]

50.

Gallant C, Luczon R, Ryan D, Good D. Investigating cannabis use and associated symptoms among university students with and without a history of concussion. Neuropsychol Rehabil. 2022;32:967–91. [DOI] [PubMed]

51.

MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9. [DOI] [PubMed]

52.

Cushman D, McCormick Z, Casey E, Plastaras CT. Discrepancies in describing pain: is there agreement between numeric rating scale scores and pain reduction percentage reported by patients with musculoskeletal pain after corticosteroid injection? Pain Med. 2015;16:870–6. [DOI] [PubMed]

53.

Silverberg ND, Iaccarino MA, Panenka WJ, Iverson GL, McCulloch KL, Dams-O’Connor K, et al.; American Congress of Rehabilitation Medicine Brain Injury Interdisciplinary Special Interest Group Mild TBI Task Force. Management of concussion and mild traumatic brain injury: a synthesis of practice guidelines. Arch Phys Med Rehabil. 2020;101:382–93. [DOI] [PubMed]

54.

Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19:37. [DOI] [PubMed] [PMC]

55.

Ware MA, Wang T, Shapiro S, Collet JP; COMPASS study team. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain. 2015;16:1233–42. [DOI] [PubMed]

56.

Russell C, Rueda S, Room R, Tyndall M, Fischer B. Routes of administration for cannabis use – basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 2018;52:87–96. [DOI] [PubMed]

57.

Lo LA, MacCallum CA, Yau JC, Barr AM. Differences in those who prefer smoking cannabis to other consumption forms for mental health: what can be learned to promote safer methods of consumption? J Addict Dis. 2023;41:258–62. [DOI] [PubMed]

58.

Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107:e1–12. Erratum in: Am J Public Health. 2018;108:e2. [DOI] [PubMed] [PMC]

59.

Tashkin DP. Marijuana and lung disease. Chest. 2018;154:653–63. [DOI] [PubMed]

60.

Piano MR. Cannabis smoking and cardiovascular health: it’s complicated. Clin Pharmacol Ther. 2017;102:191–3. [DOI] [PubMed]

61.

Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477–82. [DOI] [PubMed] [PMC]

62.

Lim CCW, Chan GCK, Wadsworth E, Stjepanović D, Chiu V, Chung JYC, et al. Trends and socio-demographic differences of cannabis vaping in the USA and Canada. Int J Environ Res Public Health. 2022;19:14394. [DOI] [PubMed] [PMC]

63.

Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44–50. [DOI] [PubMed]

64.

Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO. Cannabis use patterns and motives: a comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addict Behav. 2017;72:14–20. [DOI] [PubMed] [PMC]

65.

Stith SS, Li X, Orozco J, Lopez V, Brockelman F, Keeling K, et al. The effectiveness of common Cannabis products for treatment of nausea. J Clin Gastroenterol. 2022;56:331–8. [DOI] [PubMed]

66.

Musty RE, Rossi R. Effects of smoked cannabis and oral δ⁹-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy. J Cannabis Ther. 2001;1:29–56. [DOI]

67.

Sagar KA, Dahlgren MK, Lambros AM, Smith RT, El-Abboud C, Gruber SA. An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J Int Neuropsychol Soc. 2021;27:648–60. [DOI] [PubMed]

68.

Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med (Lond). 2022;2:139. [DOI] [PubMed] [PMC]

69.

Eadie L, Lo LA, Christiansen A, Brubacher JR, Barr AM, Panenka WJ, et al. Duration of neurocognitive impairment with medical cannabis use: a scoping review. Front Psychiatry. 2021;12:638962. [DOI] [PubMed] [PMC]

70.

McVige J, Kaur D, Hart P, Lillis M, Mechtler L, Bargnes V, et al. Medical cannabis in the treatment of post-traumatic concussion (P3.9-027). Neurology. 2019;92:P3.9-027.

71.

Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8:2861. Erratum in: Sci Rep. 2022;12:14856. [DOI] [PubMed] [PMC]

72.

Langer LK, Alavinia SM, Lawrence DW, Munce SEP, Kam A, Tam A, et al. Prediction of risk of prolonged post-concussion symptoms: derivation and validation of the TRICORDRR (Toronto Rehabilitation Institute Concussion Outcome Determination and Rehab Recommendations) score. PLoS Med. 2021;18:e1003652. [DOI] [PubMed] [PMC]

73.

Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43:128–35. [DOI] [PubMed]

74.

O’Connor TA, Panenka WJ, Livingston EM, Stubbs JL, Askew J, Sahota CS, et al. Traumatic brain injury in precariously housed persons: incidence and risks. EClinicalMedicine. 2022;44:101277. [DOI] [PubMed] [PMC]

75.

MacCallum CA, Eadie L, Barr AM, Boivin M, Lu S. Practical strategies using medical cannabis to reduce harms associated with long term opioid use in chronic pain. Front Pharmacol. 2021;12:633168. [DOI] [PubMed] [PMC]

76.

Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2:160–6. [DOI] [PubMed] [PMC]

77.

Corroon JM Jr, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs – a cross-sectional study. J Pain Res. 2017;10:989–98. [DOI] [PubMed] [PMC]

78.

Brammer WA, Conn BM, Iverson E, Lankenau SE, Dodson C, Wong CF. Coping motives mediate the association of trauma history with problematic cannabis use in young adult medical cannabis patients and non-patient cannabis users. Subst Use Misuse. 2022;57:684–97. [DOI] [PubMed]

79.

Adams RS, Corrigan JD, Dams-O’Connor K. Opioid use among individuals with traumatic brain injury: a perfect storm? J Neurotrauma. 2020;37:211–6. [DOI] [PubMed] [PMC]

80.

Gritsenko V, Kogan M, Konstantinov V, Marinova T, Reznik A, Isralowitz R. Religion in Russia: its impact on university student medical cannabis attitudes and beliefs. Complement Ther Med. 2020;54:102546. [DOI] [PubMed]